Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | IDH1 | O75874 | 3/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31746812 | 0.86 | IDH1 (0.48) | BRD4IDH1BRAF | |
| SCHEMBL3496028 | 0.82 | BRD4 (0.52) | BRD4MAPK8 | |
| SCHEMBL17895234 | 0.81 | IKBKB (0.57) | IKBKBMAPK8HTR3EHTR3BHTR3A | |
| SCHEMBL3497122 | 0.81 | HTR3E (0.38) | BRD4IDH1HTR3EHTR3BHTR3A | |
| SCHEMBL31746848 | 0.79 | HTR3E (0.44) | IDH1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31746633 | 0.78 | IDH1 (0.46) | IDH1BRAF | |
| SCHEMBL31746726 | 0.78 | ABL1 (0.43) | IDH1KDM4EBRAF | |
| SCHEMBL31746824 | 0.78 | ABL1 (0.43) | IDH1BRAF | |
| SCHEMBL17895265 | 0.78 | IKBKB (0.57) | IKBKBBRD4IDH1CHUKBRAF | |
| SCHEMBL31746664 | 0.77 | IKBKB (0.46) | IKBKBIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | IKBKB 1832/4885BRD4 222/4885IDH1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.